JP2005535560A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535560A5 JP2005535560A5 JP2003547390A JP2003547390A JP2005535560A5 JP 2005535560 A5 JP2005535560 A5 JP 2005535560A5 JP 2003547390 A JP2003547390 A JP 2003547390A JP 2003547390 A JP2003547390 A JP 2003547390A JP 2005535560 A5 JP2005535560 A5 JP 2005535560A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- heteroaryl
- substituted
- tetrahydro
- carboxamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 41
- 125000001072 heteroaryl group Chemical group 0.000 claims 25
- 125000000623 heterocyclic group Chemical group 0.000 claims 21
- 125000003118 aryl group Chemical group 0.000 claims 11
- -1 N 3 Chemical class 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 9
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 5
- 125000001997 phenyl group Chemical class [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 5
- 125000003107 substituted aryl group Chemical group 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000001589 carboacyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 2
- 125000006648 (C1-C8) haloalkyl group Chemical group 0.000 claims 1
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- LBYVZRFDLNAPRC-UHFFFAOYSA-N 2-sulfanylguanidine Chemical compound NC(=N)NS LBYVZRFDLNAPRC-UHFFFAOYSA-N 0.000 claims 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 claims 1
- LOIFMZWJXUUQMN-UHFFFAOYSA-N 7-chloro-n-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound CC1=NC=CC=C1OC(N=C1)=CC=C1NC(=O)N1CCC2=CC(Cl)=CC=C2CC1 LOIFMZWJXUUQMN-UHFFFAOYSA-N 0.000 claims 1
- 102000014630 G protein-coupled serotonin receptor activity proteins Human genes 0.000 claims 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims 1
- WRWYGOVGIGCDLE-UHFFFAOYSA-N [O]c1ccccc1F Chemical group [O]c1ccccc1F WRWYGOVGIGCDLE-UHFFFAOYSA-N 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 150000001409 amidines Chemical class 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- QGBSISYHAICWAH-UHFFFAOYSA-N dicyandiamide Chemical compound NC(N)=NC#N QGBSISYHAICWAH-UHFFFAOYSA-N 0.000 claims 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- AIESVUFSIFALRX-UHFFFAOYSA-N n-(1-azabicyclo[2.2.2]octan-3-yl)-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound C1CC2=CC=CC=C2CCN1C(=O)NC1C(CC2)CCN2C1 AIESVUFSIFALRX-UHFFFAOYSA-N 0.000 claims 1
- JTPPOWSXYXUMSY-UHFFFAOYSA-N n-(2-chloropyridin-3-yl)-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound ClC1=NC=CC=C1NC(=O)N1CCC2=CC=CC=C2CC1 JTPPOWSXYXUMSY-UHFFFAOYSA-N 0.000 claims 1
- DADLXCCWSHYYIK-UHFFFAOYSA-N n-(6-chloropyridin-3-yl)-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound C1=NC(Cl)=CC=C1NC(=O)N1CCC2=CC=CC=C2CC1 DADLXCCWSHYYIK-UHFFFAOYSA-N 0.000 claims 1
- XPXYUVIUHGNRCC-UHFFFAOYSA-N n-[6-(2,4-dichlorophenoxy)pyridin-3-yl]-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1OC(N=C1)=CC=C1NC(=O)N1CCC2=CC=CC=C2CC1 XPXYUVIUHGNRCC-UHFFFAOYSA-N 0.000 claims 1
- QOJIZDFOYWQHFU-UHFFFAOYSA-N n-[6-(2-methylpyridin-3-yl)oxypyridin-3-yl]-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound CC1=NC=CC=C1OC(N=C1)=CC=C1NC(=O)N1CCC2=CC=CC=C2CC1 QOJIZDFOYWQHFU-UHFFFAOYSA-N 0.000 claims 1
- XEPITPCMSQVJDT-UHFFFAOYSA-N n-[6-(4-chloro-2-methylphenoxy)pyridin-3-yl]-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound CC1=CC(Cl)=CC=C1OC(N=C1)=CC=C1NC(=O)N1CCC2=CC=CC=C2CC1 XEPITPCMSQVJDT-UHFFFAOYSA-N 0.000 claims 1
- FCWDZCGGDFWTLX-UHFFFAOYSA-N n-[6-(4-chloro-3,5-dimethylphenoxy)pyridin-3-yl]-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound CC1=C(Cl)C(C)=CC(OC=2N=CC(NC(=O)N3CCC4=CC=CC=C4CC3)=CC=2)=C1 FCWDZCGGDFWTLX-UHFFFAOYSA-N 0.000 claims 1
- RKUOKQMRGCIRTE-UHFFFAOYSA-N n-[6-(4-chloro-3-methylphenoxy)pyridin-3-yl]-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound C1=C(Cl)C(C)=CC(OC=2N=CC(NC(=O)N3CCC4=CC=CC=C4CC3)=CC=2)=C1 RKUOKQMRGCIRTE-UHFFFAOYSA-N 0.000 claims 1
- UDIAJTAJODNTHO-UHFFFAOYSA-N n-[6-(4-chlorophenoxy)pyridin-3-yl]-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound C1=CC(Cl)=CC=C1OC(N=C1)=CC=C1NC(=O)N1CCC2=CC=CC=C2CC1 UDIAJTAJODNTHO-UHFFFAOYSA-N 0.000 claims 1
- OMRMKCRSFXDCHD-UHFFFAOYSA-N n-[6-(4-methoxyphenoxy)pyridin-3-yl]-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound C1=CC(OC)=CC=C1OC(N=C1)=CC=C1NC(=O)N1CCC2=CC=CC=C2CC1 OMRMKCRSFXDCHD-UHFFFAOYSA-N 0.000 claims 1
- WXMCHJDHHAHRIC-UHFFFAOYSA-N n-piperidin-3-yl-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound C1CC2=CC=CC=C2CCN1C(=O)NC1CCCNC1 WXMCHJDHHAHRIC-UHFFFAOYSA-N 0.000 claims 1
- FVTWMFRLDLEXHF-UHFFFAOYSA-N n-pyridin-3-yl-1,2,4,5-tetrahydro-3-benzazepine-3-carboxamide Chemical compound C1CC2=CC=CC=C2CCN1C(=O)NC1=CC=CN=C1 FVTWMFRLDLEXHF-UHFFFAOYSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 125000005505 thiomorpholino group Chemical group 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33401201P | 2001-11-28 | 2001-11-28 | |
| PCT/US2002/037715 WO2003045940A2 (en) | 2001-11-28 | 2002-11-26 | Benzazepine derivatives and their use as 5-ht ligands |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535560A JP2005535560A (ja) | 2005-11-24 |
| JP2005535560A5 true JP2005535560A5 (enExample) | 2006-01-19 |
Family
ID=23305178
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003547390A Withdrawn JP2005535560A (ja) | 2001-11-28 | 2002-11-26 | 治療用の化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6861420B2 (enExample) |
| EP (1) | EP1451176A2 (enExample) |
| JP (1) | JP2005535560A (enExample) |
| AU (1) | AU2002346507A1 (enExample) |
| BR (1) | BR0214529A (enExample) |
| CA (1) | CA2468010A1 (enExample) |
| MX (1) | MXPA04005151A (enExample) |
| WO (1) | WO2003045940A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003076426A2 (en) * | 2002-03-04 | 2003-09-18 | Pharmacia & Upjohn Company | Pyridinyloxy derivatives as 5-ht receptor ligands |
| TW200510324A (en) * | 2003-08-11 | 2005-03-16 | Lilly Co Eli | 6-(2,2,2-trifluoroethylamino)-7-chiloro-2, 3, 4, 5-tetrahydro-1h-benzo[d]azepine as a 5-ht2c receptor agonist |
| EP2479168B1 (en) | 2004-02-25 | 2014-04-09 | Eli Lilly And Company | 6-Substituted 2,3,4,5-Tetrahydro-1H-Benzo [d]Azepines as 5-HT2C Receptor Agonists |
| EP1728520A1 (de) * | 2005-05-04 | 2006-12-06 | Charité - Universitätsmedizin Berlin | Verwendung von spezifisch an das Serotonin-Transport-Protein (SERT) bindenden Radiopharmaka zur Herstellung eines Diagnostikums zur Untersuchung von Kopfschmerzerkrankungen |
| WO2006117218A2 (en) * | 2005-05-04 | 2006-11-09 | Charite Universitätsmedizin - Berlin | Serotonin-transport-protein binding radiopharmaceutical for the production of a diagnostic medicament for the diagnosis of headache |
| PT1924560E (pt) * | 2005-09-01 | 2009-10-23 | Lilly Co Eli | 2,3,4,5-tetra-hidro-1h-benzo[d]azepinas como agonistas de receptores 5-ht2c |
| ES2397400T3 (es) | 2005-09-01 | 2013-03-06 | Eli Lilly & Company | 6-arilalquilamino-2,3,4,5-tetrahidro-1H-benzo[D]azepinas como agonistas del receptor 5-HT2C |
| WO2007028132A2 (en) | 2005-09-01 | 2007-03-08 | Eli Lilly And Company | 6-N-LINKED HETEROCYCLE-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS |
| BRPI0615033A2 (pt) | 2005-09-01 | 2011-04-26 | Lilly Co Eli | composto, composição farmacêutica, e, uso de um composto |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5132311A (en) * | 1990-06-27 | 1992-07-21 | G. D. Searle & Co. | Cyanoquanidine type III antiarrhythmic agents and use |
| GB9612883D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| GB9612885D0 (en) | 1996-06-20 | 1996-08-21 | Smithkline Beecham Plc | Novel compounds |
| AU2001264376A1 (en) * | 2000-06-15 | 2001-12-24 | Chaconne Nsi Co., Ltd. | Urea derivative useful as an anti-cancer agent and process for preparing same |
-
2002
- 2002-11-26 CA CA002468010A patent/CA2468010A1/en not_active Abandoned
- 2002-11-26 MX MXPA04005151A patent/MXPA04005151A/es unknown
- 2002-11-26 BR BRPI0214529-4A patent/BR0214529A/pt not_active IP Right Cessation
- 2002-11-26 EP EP02784572A patent/EP1451176A2/en not_active Withdrawn
- 2002-11-26 US US10/305,408 patent/US6861420B2/en not_active Expired - Fee Related
- 2002-11-26 JP JP2003547390A patent/JP2005535560A/ja not_active Withdrawn
- 2002-11-26 WO PCT/US2002/037715 patent/WO2003045940A2/en not_active Ceased
- 2002-11-26 AU AU2002346507A patent/AU2002346507A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240400586A1 (en) | Heteroaryl derivative parp inhibitor and use thereof | |
| EP3728188B1 (en) | Aryl and heteroaryl substituted indole compounds | |
| JP7313354B2 (ja) | Ｔｌｒ阻害剤として有用なアミド置換されたインドール化合物 | |
| US20230346927A1 (en) | COMBINATION of ATR KINASE INHIBITORS and PD-1/PD-L1 INHIBITORS | |
| TWI592158B (zh) | 經取代之２，３－二氫咪唑并［１，２－ｃ］喹唑啉鹽 | |
| EP3402795B1 (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| TWI617552B (zh) | 用於激酶調節及其適應症之化合物及方法 | |
| US20140357636A1 (en) | Treatment of Skeletal-Related Disorders | |
| US20090082343A1 (en) | 1,3-benzothiazinone derivatives and use thereof | |
| JP2009532464A5 (enExample) | ||
| JP2003512374A5 (enExample) | ||
| JP2008513498A5 (enExample) | ||
| JP2003512353A5 (enExample) | ||
| JP2003501420A5 (enExample) | ||
| JP2010512338A5 (enExample) | ||
| US20250346571A1 (en) | Bicyclic derivative parp inhibitor and use thereof | |
| JP2005535560A5 (enExample) | ||
| WO2018206547A1 (en) | Combination of bub1 and atr inhibitors | |
| WO2018153973A1 (en) | Combination of atr kinase inhibitors with parp inhibitors | |
| JP2022548907A (ja) | ベンズイミダゾールおよびそれを使用する方法 | |
| WO2018153971A1 (en) | Combination of atr kinase inhibitors | |
| JP2013518823A5 (enExample) | ||
| WO2018153972A1 (en) | Combination of atr kinase inhibitors and antiandrogens | |
| JP2003516994A5 (enExample) | ||
| CN111801322B (zh) | 用于治疗中枢和周边神经系统病症的激酶抑制剂 |